



---

---

---

---

---

---

---

---

---

---

### Conflict of Interest Statement

- Most manufacturers of prescription opioids or stimulants subscribe to RADARS System.
- RADARS System is the property of Denver Health and Hospital Authority, a political subdivision of the State of Colorado.
- Subscribers receive information, but do not participate in developing the System, data collection, or analysis. They do not have access to the raw data.
- Employees are prohibited from personal financial relationships with any company.

2

---

---

---

---

---

---

---

---

---

---



---

---

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

---

---

- ### Data Needs
- |  |   |
|--|---|
| <p><b>Substance Abuse</b></p> <ul style="list-style-type: none"> <li>• Timely</li> <li>• Geographic specificity</li> <li>• Accuracy</li> <li>• Trending</li> </ul> | <p><b>Regulatory</b></p> <ul style="list-style-type: none"> <li>• Substance Abuse, plus             <ul style="list-style-type: none"> <li>◦ Product specificity</li> <li>◦ Faster</li> <li>◦ Subpopulations</li> </ul> </li> </ul> |
|--|---|
- 5

---

---

---

---

---

---

---

---

---

---

- ### Data Available
- |  |  |
|--|--|
| <p><b>Single Perspective</b></p> <ul style="list-style-type: none"> <li>• Federal             <ul style="list-style-type: none"> <li>◦ Drug Abuse Warning Network (DAWN)</li> <li>◦ National Survey of Drug Use and Health (NSDUH)</li> <li>◦ Treatment Episode Dataset (TEDS)</li> <li>◦ National Vital Statistic System (NVSS)</li> <li>◦ National Forensic Laboratory System (NFLIS)</li> </ul> </li> <li>• National Poison Data System (NPDS)</li> <li>• IQVIA</li> <li>• Symphony Health</li> </ul> | <p><b>Multiple perspective</b></p> <ul style="list-style-type: none"> <li>• RADARS System             <ul style="list-style-type: none"> <li>◦ IQVIA</li> <li>◦ Poison Centers</li> <li>◦ Substance abuse treatment centers</li> <li>◦ Drug diversion investigators</li> <li>◦ Nationally representative survey</li> <li>◦ StreetRx</li> <li>◦ Researchers and Patients Interacting Directly (RAPID)</li> <li>◦ Web monitoring</li> <li>◦ Coroner/NDI/DIM</li> </ul> </li> <li>• Inflexxion Navippro             <ul style="list-style-type: none"> <li>◦ Treatment Centers</li> </ul> </li> </ul> |
|--|--|
- 6

---

---

---

---

---

---

---

---

---

---



---

---

---

---

---

---

---

---

How do we put this information together?

---

---

---


---

---

---

---

---



---

---

---

---

---

---

---

---

## Unanticipated Consequences

The NEW ENGLAND JOURNAL of MEDICINE

Case Studies in Social Medicine

PERSPECTIVE  
Pharmaceutical Protections in U.S. Trade Deals — What Do Americans Get in Return...

ORIGINAL ARTICLE  
Transcatheter Aortic-Valve Replacement with a Ballon Expandable Valve in Low-Risk

### Perspective

## No Shortcuts to Safer Opioid Prescribing

Deborah Dowell, M.D., M.P.H., Tamara Haegerich, Ph.D., and Roger Chou, M.D.

<https://healthprofessionalsforpatientsinpain.org/>

• 10

---

---

---

---

---

---

---

---


---

---

---

---

## Is Rx Drug Abuse Decreasing?



• Analgesics: oxycodone, hydrocodone, hydromorphone, fentanyl, morphine, and tramadol

---

---

---

---

---

---

---

---


---

---

---

---

## Medical Examiner Data National Vital Statistics System, CDC



• 12

---

---

---

---

---

---

---

---


---

---

---

---

## Deaths from Prescription Opioids are Decreasing Substantially



13

---

---

---

---

---

---

---

---

---

---

Data from multiple systems indicate that Rx abuse and mortality are decreasing

...

14

---

---

---

---

---

---

---

---

---

---

### Do abuse deterrent opioid formulations work?

Richard C. Dart, MD, PhD; Janetta L. Iwanicki, MD; Nabarun Dasgupta, PhD; Theodore J. Cicero, PhD; Sidney H. Schnoll, MD, PhD

15

---

---

---

---

---

---


---

---

---

---

## Opioid Rx Dispensed in US, 2009 - 2015



Severtson SG, et al. Drug Alcohol Depend 2016;168:219-229

16

---

---

---

---

---

---


---

---

---

---

## OxyContin v. Comparators in 4 Programs



J Opioid Management 2017; DOI:10.5055/jom.2017.0000

17

---

---

---

---

---

---

---


---

---

---

## Drug Diversion, Drugs Involved 2009 - 2015

- 250 law enforcement investigators in 49 states



18

18

---

---

---

---

---

---


---

---

---

---

### OxyContin v. Comparators in 4 Programs



J Opioid Management 2017; DOI:10.5055/jom.2017.0000 19

---

---

---

---

---

---


---

---

---

---

### Past Year Nonmedical Use of OxyContin® NSDUH, 2006 – 2014



20

---

---

---

---

---

---

---

---

---

---

The ADF version of OxyContin has decreased abuse, non-oral abuse in multiple systems in 3 different countries.

...

21

---

---

---

---

---

---


---

---

---

---

## Understanding the Opioid Epidemic



National Vital Statistics System, Centers for Disease Control, 2017

22

---

---

---

---

---

---


---

---

---

---

## Is Total Substance Abuse Increasing?



National Survey of Drug Use and Health, US Centers for Disease Control, 2017

23

---

---

---

---

---

---


---

---

---

---

## Opioid Epidemic Epidemic of Opioid Deaths



National Vital Statistics System, Centers for Disease Control, 2017

24

---

---

---

---

---

---

---

---

---

---



## Recomendations

- **John Peppin**
  - Required Pain/opioid Education for Medical Boards.
  - Standardized requirements for Medical Examiners for all states:
  - Updating of Death Certificates.
- **John Coleman**
  - HHS should adopt clinical modifications to address the ambiguities in the current ICD-10-T-codes for categorizing drug-related mortality.
  - The Public Health Service Act should be amended to require states to use CDC-supplied error-avoidance software in preparing and submitting copies of e-Vital electronic death certificates via a restricted CDC portal.
- **Rick Dart**
  - ADFs should be promoted and compensated by payers
  - US drug policy should focus on demand reduction like Health Communities and Project Lazarus
  - Supply reduction will be even more difficult in the age of fentanyl

• 25

---

---

---

---

---

---

---

---

---

---

## Questions?

[Richard.Dart@rmpdc.org](mailto:Richard.Dart@rmpdc.org)

• 26

---

---

---

---

---

---

---

---

---

---